Preclinical evaluation of DOTAGA.Glu.(FAPI)2 and DO3A.Glu.(FAPI)2 as theranostics with human dosimetry extrapolation to lutetium-177 and terbium-161 analogs
These results support the potential clinical translation of DOTAGA.Glu.(FAPI)<sub>2</sub> and DO3A.Glu.(FAPI)<sub>2</sub>, as promising candidates for precise diagnosis and treatment of FAP-expressing malignancies.
Authors
- Adrianna Bilinska
- Eleni Gourni (ORCID: https://orcid.org/0000-0003-2198-382X)
- Tilman Läppchen (ORCID: https://orcid.org/0000-0002-7746-1572)
- Silvano Gnesin (ORCID: https://orcid.org/0000-0002-6547-3824)
- Marcel Martin (ORCID: https://orcid.org/0009-0007-9817-7996)
- Axel Rominger (ORCID: https://orcid.org/0000-0002-1954-736X)
- Naveen Kumar (ORCID: https://orcid.org/0000-0001-6176-6913)
- Frank Rösch
- Elena Menéndez
Institutions
- University of Bern (CH)
- Johannes Gutenberg University Mainz (DE)
- University Hospital of Bern (CH)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- University of Lausanne (CH)
Publication Details
- Journal
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2025-10-17
- DOI
- https://doi.org/10.1007/s00259-025-07565-9
- Citations
- 2
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- University of Bern
- European Commission
- HORIZON EUROPE Framework Programme